Evaluation of brexpiprazole as adjunctive therapy in treatment-resistant depression: Real-world data

Read full text Summarise with VIRAT
Authors: Hüseyin Kara, Ali Erdogan
Cited by: 0
References: 27

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: Brexpiprazole (BRX) is an antipsychotic used as an adjunctive agent in the treatment of major depressive disorder. We aimed to evaluate the effectiveness of BRX in treatment-resistant depression (TRD). Method: This study was conducted between May 1, 2024 and January 1, 2025. Medical records of patients who were started on BRX as adjunctive treatment for TRD were retrospectively reviewed. Patient files containing sociodemographic data and scores from the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Global Assessment Scale (GAS) were included in the analysis. Results: A total of 30 patients were included in the study. The mean age was 32.50±11.38 years (range: 18-63), and 63.3% (n=19) were female. The median BRX dose was 2 mg/day. Of the 30 patients, 20 (66.7%) continued treatment regularly. Among those who discontinued treatment, three patients stopped due to akathisia, two due to sedation, and two due to an urgent need for electroconvulsive therapy. For the 20 patients who continued treatment, scale scores were reassessed during follow-up visits between weeks 4 and 8. A significant improvement was observed in both BDI scores (32.05±8.96 vs. 12.45±9.74; p

Fields of Study & Subjects

Treatment of Major Depression Schizophrenia research and treatment Electroconvulsive Therapy Studies

Publication details

Journal / source
Dusunen Adam The Journal of Psychiatry and Neurological Sciences
Volume
39
Issue
1
Pages
52–58
Publication date
1 March 2026
Language
EN